Etoricoxib-Induced Erythema-Multiforme-Like Eruption

  title={Etoricoxib-Induced Erythema-Multiforme-Like Eruption},
  author={Laurence Thirion and Arjen F. Nikkels and G{\'e}rald E. Pi{\'e}rard},
  pages={227 - 228}
Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature. 

Figures from this paper

Etoricoxib-induced pretibial erythema and edema

A case of extoricoxib-induced pretibial erythema and edema and a review of the literature on cox-2 inhibitor side effects is reported.

Fixed drug eruption caused by etoricoxib – 2 cases confirmed by patch testing

This work presents two cases of FDE caused by etoricoxib, a recently developed but widely used selective cyclo-oxygenase (COX) isoenzyme 2 inhibitor, which has rarely been described as a cause ofFDE.

Rare Case of Etoricoxib-Induced Oral Ulceration

The clinicians should be aware of the unwanted side effect of etoricoxib as well as the other COX-2 inhibitors that can cause oral ulcer even though it rarely occurs.

Bullous Reactions Associated With COX-2 Inhibitors.

CASE REPORTA 52-year-old man presented with a rash, which had been present for 2 days before his clinic visit. The rash developed 8 days after inception of oral treatment with etoricoxib, 60 mg o.d.

A case report on toxic epidermal necrolysis with etoricoxib

A patient who developed TEN after treatment with etoricoxib for osteoarthritis that later resolved in 15 days after withdrawal and symptomatic treatment is summarized.

Etoricoxib-induced fixed drug eruption with positive lesional patch tests

The patch test was reliable for the diagnosis of FDE, avoiding the need for subsequent oral provocation testing and therefore preventing the possible adverse effects of etoricoxib, despite being regarded as a safe drug.

Mucosal exfoliation as a selective reaction to etoricoxib

Etoricoxib is a non‐steroidal anti‐inflammatory drug (NSAID) that inhibits the inducible cyclooxygenase (COX‐2) with a good safety profile.

Epidermal necrolysis in the context of immuno‐oncologic medication as well as kinase inhibitors and biologics

An increasing number of case notifications in the context with new immuno‐oncologic drugs, kinase inhibitors and biologics have been observed.

Oral adverse reactions associated with etoricoxib, a common pain medication.



Acute Generalized Exanthematic Pustulosis: A Case and an Overview of Side Effects Affecting the Skin Caused by Celecoxib and Other COX-2 Inhibitors Reported So Far

A 55-year-old woman who was treated for periarthritis humeroscapularis with celecoxib (Celebrex) developed a generalized pustular exanthema on the head and upper trunk, accompanied by fever, leukocytosis and increased erythrocyte sedimentation rate, and the pustules disappeared without any treatment.

Serious Skin Reactions and Selective COX-2 Inhibitors

A retrospective review of information from reports of serious skin reactions reported during prescription-event monitoring (PEM) studies of rofecoxib, celecoxib, etoricoxib and valdecoxib conducted in England since 1999 provides useful and complementary information to other published studies about serious skin reaction reported during treatment with COX-2 selective inhibitors.

Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.

Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.

Anti-inflammatory and antirheumatic drugs.

Excerpt Meclofenamate sodium (Meclomen), a nonsteroidal anti-inflammatory agent of the fenamate group, has recently been approved by the U.S. Food and Drug A...

Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.

  • J. QuiralteJ. Delgado J. Conde
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2004

Etoricoxib: A Highly Selective COX-2 Inhibitor

Efficacy for acute pain has been evaluated in acute gout, primary dysmenorrhea, and dental surgery and for chronic pain in rheumatoid arthritis, osteoarthritis, and chronic lower back pain and the cardiovascular adverse effects of selective COX-2 inhibition are not well defined.

Le médicament du mois : Etoricoxib (Arcoxia®)

L'efficacite de l'etoricoxib a ete evaluee dans de nombreuses etudes controlees randomisees, montrant une efficacite identique aux autres AINS non selectifs avec moins d'effets secondaires au niveau gastro-intestinal.

COX-2 selective nonsteroidal anti-inflammatory drugs: current status.

COX-2 inhibitors can also result into increase blood pressure, macular eruptions, urticaria, pseudoporphyria, erythema multiforme, oedema, worsening of heart failure, fatal allergic vasculitis and aggravation of doxorubicin-mediated cardiac injury.